N. Umesaki et al., Intermittent cisplatin therapy for stage-III ovarian cancer patients following clinical remission, GYNECOL OBS, 47(2), 1999, pp. 139-143
Intermittent cisplatin (CDDP) administration as consolidation therapy for s
tage-III ovarian cancer was studied. No patients with residual disease at s
urgery or at second-look operation or patients with <8 U/ml of CA125 after
remission induction chemotherapy were enrolled in this study. Fifteen subje
cts received intermittent chemotherapy, and 10 control patients did not. CD
DP of 20 mg/m(2) for 5 days was administered every 3-4 months for 5 years.
A significant increase in 5-year survival rate was found in the intermitten
t chemotherapy group when compared with the control group. Side effects fro
m the intermittent chemotherapy were controllable. Intermittent CDDP therap
y seems to be an effective consolidation therapy for stage-ill ovarian canc
er patients.